Cargando…

Serious Neurological Adverse Events of Ceftriaxone

We described ceftriaxone-induced CNS adverse events through the largest case series of Adverse Drug Reactions (ADRs) reports, from 1995 to 2017, using the French Pharmacovigilance Database. In total, 152 cases of serious CNS ADRs were analyzed; 112 patients were hospitalized or had a prolonged hospi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lacroix, Clémence, Bera-Jonville, Annie-Pierre, Montastruc, François, Velly, Lionel, Micallef, Joëlle, Guilhaumou, Romain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148437/ https://www.ncbi.nlm.nih.gov/pubmed/34066591 http://dx.doi.org/10.3390/antibiotics10050540

Ejemplares similares

French Pharmacovigilance Public System and COVID-19 Pandemic
por: Grandvuillemin, Aurélie, et al.
Publicado: (2020)

COVID-19 and NSAIDs: Primum non nocere
por: Micallef, Joëlle, et al.
Publicado: (2020)

Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection
por: Micallef, Joëlle, et al.
Publicado: (2020)

What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps?
por: Lacroix, Clémence, et al.
Publicado: (2022)

101. Serious Adverse Event Rates for Cefazolin and Ceftriaxone Outpatient Parenteral Antimicrobial Therapy
por: Sunagawa, Shawnalyn, et al.
Publicado: (2023)

Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy
por: Soeiro, Thomas, et al.
Publicado: (2021)

French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge
por: Lacroix, Clémence, et al.
Publicado: (2021)

Pharmacovigilance des médicaments et des vaccins contre la COVID-19 durant la pandémie : comment le Réseau français des centres régionaux de pharmacovigilance a relevé le défi ?
por: Jonville-Bera, Annie Pierre, et al.
Publicado: (2023)

Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: A win-win bet with Health Authorities!
por: Jonville-Bera, Annie Pierre, et al.
Publicado: (2023)

Serious adverse drug reactions with hydroxychloroquine: a pharmacovigilance study in Vigibase®
por: Montastruc, Jean-Louis, et al.
Publicado: (2020)

A serious nightmare: psychiatric and neurologic adverse reactions to mefloquine are serious adverse reactions
por: Nevin, Remington L.
Publicado: (2017)

Serious Neurological Adverse Events after Ivermectin—Do They Occur beyond the Indication of Onchocerciasis?
por: Chandler, Rebecca E.
Publicado: (2018)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018)

1969. Comparison of Adverse Event Rates Between Patients Treated With Ceftaroline or Ceftriaxone
por: Jansen, Jeffrey W, et al.
Publicado: (2018)

Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019: a retrospective case–noncase study
por: Chouchana, Laurent, et al.
Publicado: (2021)

Cannabis Use: Signal of Increasing Risk of Serious Cardiovascular Disorders
por: Jouanjus, Emilie, et al.
Publicado: (2014)

Identification of serious, unpredictable adverse events with tocilizumab
Publicado: (2020)

Spontaneous Reports of Serious Adverse Drug Reactions Resulting From Drug–Drug Interactions: An Analysis From the French Pharmacovigilance Database
por: Létinier, Louis, et al.
Publicado: (2021)

Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review
por: Madi, Karima, et al.
Publicado: (2023)

Augmentation des surdosages et des décès en lien avec la consommation de méthadone durant la crise sanitaire liée au COVID 19 au regard des tendances observées en 2019
por: Frauger, Elisabeth, et al.
Publicado: (2021)

Serious adverse events associated with yellow fever vaccine
por: de Menezes Martins, Reinaldo, et al.
Publicado: (2015)

Analysis of serious adverse event: Writing a narrative
por: Nambiar, Indu
Publicado: (2018)

Serious neurological adverse events following immunization against SARS-CoV-2: a narrative review of the literature
por: Eslait-Olaciregui, Sara, et al.
Publicado: (2023)

Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases: Illustration From the Experience of the French Addictovigilance Network
por: Soeiro, Thomas, et al.
Publicado: (2021)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
por: Zhao, Bin, et al.
Publicado: (2019)

β-Lactam Pharmacokinetic/Pharmacodynamic Target Attainment in Intensive Care Unit Patients: A Prospective, Observational, Cohort Study
por: Guilhaumou, Romain, et al.
Publicado: (2023)

Atypical thrombosis associated with VaxZevria® (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres
por: Gras-Champel, Valérie, et al.
Publicado: (2021)

Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis
por: Awadzi, Kwablah
Publicado: (2003)

Influenza Vaccination of Pregnant Women and Serious Adverse Events in the Offspring
por: Donzelli, Alberto
Publicado: (2019)

Artificial Intelligence for Unstructured Healthcare Data: Application to Coding of Patient Reporting of Adverse Drug Reactions
por: Létinier, Louis, et al.
Publicado: (2021)

Neurologic adverse events of cancer immunotherapy
por: de Brito, Marcelo Houat
Publicado: (2022)

Incidence and preventability of hospital admissions for adverse drug reactions in France: A prospective observational study (IATROSTAT)
por: Laroche, Marie‐Laure, et al.
Publicado: (2022)

Repurposing of the β-Lactam Antibiotic, Ceftriaxone for Neurological Disorders: A Review
por: Yimer, Ebrahim M., et al.
Publicado: (2019)

Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence
por: Roustit, M., et al.
Publicado: (2020)

Surveillance of serious adverse events following immunization in resource poor settings
por: Breugelmans, Gabrielle J, et al.
Publicado: (2011)

Antipsychotics-Associated Serious Adverse Events in Children: An Analysis of the FAERS Database
por: Kimura, Goji, et al.
Publicado: (2015)

A Cancer Patient’s Experience With a Rare But Serious Adverse Event
por: RayChaudhury, Amlan
Publicado: (2019)

An HIV-infected Patient with No Serious Adverse Events after Overdosing on Raltegravir
por: Hosoda, Tomohiro, et al.
Publicado: (2019)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns
por: Touafchia, Anthony, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vlfa620imsjhfsnu9u3e0sqv6r